Patient Advocate, Jack Aiello, is a 28-year survivor of multiple myeloma. When he was diagnosed, he was told he would only have 2 to 3 years to live and there were only 2 treatment options available. Jack underwent 2 transplants, then went onto a clinical trial for thalidomide but nothing worked until a third transplant.
In this discussion, he shares how since his diagnosis there are several exciting, game changing treatments for relapsed and refractory myeloma patients, more combinations of these drugs, and even more are in clinical trials.
Joining him in this conversation is Dr. Ajai Chari, the Director of Clinical Research at the Multiple Myeloma Program at Mount Sinai in New York and Dr. Sandy Wong, a blood disease specialist at University of California, San Francisco, with a special interest in multiple myeloma.
Together they discuss bispecific antibodies, treatment side effects and emerging clinical trials.
Thank you to Janssen for its support of our patient education program!
Full story & transcript → www.thepatient...
The interview has only been edited for clarity.
Join Our Community:
Website : www.thepatient...
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
______________________________
Contents of this video:
00:00 - Intro
03:18 - What are bispecific antibodies? 
07:15 - Treatment for relapsed refractory patients
09:31 - How talquetamab is different from other bispecifics?
12:22 - What makes alnuctamab different from other bispecifics?
16:09 - What are common side effects for bispecifics?
20:52 - Lowering cytokine release syndrome with treatments
25:30 - Managing side effects for bispecifics 
29:09 - Next Steps for research
30:50 - Final takeaways
#multiplemyeloma #multiplemyelomaawareness #relapsedmyeloma #refractorymyeloma #myeloma #MMsm #bispecificantibodies #cancerresearch #cancertreatment #treatment #ASH22 #thepatientstory #cancersurvivor #patientadvocate #patientadvocacy #mountsinai #ucsf #clinicaltrials #carttherapy